During the last session, Timber Pharmaceuticals Inc. (AMEX:TMBR)’s traded shares were 1.64 million, with the beta value of the company hitting 0.13. At the end of the trading day, the stock’s price was $0.73, reflecting an intraday loss of -3.86% or -$0.03. The 52-week high for the TMBR share is $3.65, that puts it down -400.0 from that peak though still a striking 8.22% gain since the share price plummeted to a 52-week low of $0.67. The company’s market capitalization is $27.38M, and the average intraday trading volume over the past 10 days was 1.53 million shares, and the average trade volume was 811.32K shares over the past three months.
Timber Pharmaceuticals Inc. (TMBR) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 3.00. TMBR has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Timber Pharmaceuticals Inc. (TMBR) registered a -3.86% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.86% in intraday trading to $0.73 this Wednesday, 10/13/21, hitting a weekly high. The stock’s 5-day price performance is -12.05%, and it has moved by -18.21% in 30 days. Based on these gigs, the overall price performance for the year is -33.03%. The short interest in Timber Pharmaceuticals Inc. (AMEX:TMBR) is 4.22 million shares and it means that shorts have 3.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.00, which implies an increase of 93.92% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $12.00 respectively. As a result, TMBR is trading at a discount of -1543.84% off the target high and -1543.84% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 67.50%. While earnings are projected to return 89.20% in 2021.
Timber Pharmaceuticals Inc. is due to release its next quarterly earnings on May 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Timber Pharmaceuticals Inc. (AMEX:TMBR)’s Major holders
Timber Pharmaceuticals Inc. insiders own 12.99% of total outstanding shares while institutional holders control 3.98%, with the float percentage being 4.57%. Cetera Advisor Networks LLC is the largest shareholder of the company, while 17 institutions own stock in it. As of Mar 30, 2021, the company held over 0.1 million shares (or 0.28% of all shares), a total value of $0.21 million in shares.
The next largest institutional holding, with 87028.0 shares, is of Vanguard Group, Inc. (The)’s that is approximately 0.24% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $0.18 million.
Also, the Mutual Funds coming in first place with the largest holdings of Timber Pharmaceuticals Inc. (TMBR) shares are Vanguard Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund. Data provided on Mar 30, 2021 indicates that Vanguard Extended Market Index Fund owns about 87028.0 shares. This amounts to just over 0.24 percent of the company’s overall shares, with a $0.18 million market value. The same data shows that the other fund manager holds slightly less at 44100.0, or about 0.12% of the stock, which is worth about $89523.0.